Clinician to CEO · 2026-06-30 · 7 min
Key moments - from our scoring
Substance score
50 / 100
Five dimensions, 20 points each
This solo episode tackles a core mistake medtech founders make: chasing regulatory perfection by trying to prove everything at once. Rather than treating regulatory hurdles as immovable obstacles, Aade and his guest Jordan Morrison demonstrate that the real issue is often misaligned product claims. When clinical data supports one indication but the company pursues a broader label claim, they create unnecessary delays and expenses. Morrison's approach is pragmatic: conduct independent regulatory review to identify what your existing data actually proves, then launch with that narrowly-scoped claim first. This strategy unlocks revenue, real-world evidence, and funding for iterations two and three. Clinicians launching devices often assume more trials or more money solves stalled submissions, but the transcript reveals a simpler truth - taking what you've proven and getting it to market beats perfecting everything upfront. This appeals to medtech CEOs stuck in regulatory limbo, particularly those with early-stage devices where momentum and cash flow matter more than a gold-standard label.
Companies often face delays because their product claims are broader than what their clinical evidence actually supports, not because they lack data. Narrowing claims to match the evidence they already have can accelerate clearance.
If existing data strongly supports one indication, pursue clearance for that narrow claim first to generate revenue and real-world evidence, then expand to other indications in future iterations rather than delaying launch to prove everything at once.
Get an independent, agnostic regulatory review to assess what your current data genuinely proves versus what your regulatory consultant says you need to prove; this often reveals ways to salvage your evidence through narrower, market-ready claims.
Ask what your existing evidence can prove today and focus on getting that one claim through regulatory approval, rather than asking what additional data you need; this creates forward momentum and revenue that funds future expansion.
Our reviewer’s read on each dimension, with quotes from the episode.
The episode centers on one genuinely useful insight: narrowing product claims to match existing evidence accelerates market entry rather than pursuing broader claims that require more data. This is a concrete, non-obvious reversal of intuition for many medtech founders. However, the execution is repetitive - the same idea is restated 4-5 times with minimal new angles, and much of the runtime consists of throat-clearing and self-promotional framing rather than layering additional insights.
What if we take the data you have and find claims that support the data you have?
the quickest route to market Is matching your claim to the evidence that you've already generated
The core insight - scope narrowing as a go-to-market accelerant - is sensible but not particularly novel in medtech circles; regulatory consultants and experienced operators have long understood the MVP-for-claims strategy. The framing is competent rather than contrarian, and the episode lacks counterintuitive pushback or first-principles reasoning that would elevate it above standard industry wisdom.
Maybe you're not gonna get a clearance that says you can solve all of the cancers in all of the world at all of the same times with one little pill.
Get some revenue coming in so now you can build the second and third iterations
Jordan Morrison is presented as a regulatory and commercialization advisor with relevant medtech experience, but the transcript provides almost no context about her track record, companies she's worked with at scale, or specific outcomes she's driven. She functions more as a knowledgeable practitioner-consultant than a proven operator with direct P&L responsibility or major exits, which limits her credibility for a B2B operator audience.
I have agnostic experts from the very beginning
my regulatory people are gonna review what you've already done
The episode is almost entirely devoid of named examples, real company case studies, metrics, or concrete dollar figures. The breast cancer indication reference ('decrease in reoccurrence of breast cancer') is generic and unpacked. No actual submission timelines, approval data, or revenue milestones are provided - all recommendations remain at the level of abstraction and first principles.
maybe your clinical data showed, well, there is a decrease in reoccurrence of breast cancer
You've not wasted the money in the bill that you've done so far
The host poses a structured scenario with four options, which is a solid framing device, but then immediately pivots to a long monologue from the guest with minimal follow-up questions, pushback, or clarification. The host wraps with his own commentary and action items rather than pressing deeper into Jordan's reasoning, tradeoffs, or edge cases. The conversation lacks the tension and depth that would indicate sharp facilitation.
What's your choice and why?
And that distinction really matters
Computed from the transcript - who did the talking, and the words that came up most.
Are broad product claims slowing down your MedTech product's route to market without you even realising it? Many MedTech companies assume that regulatory delays mean they need more clinical evidence, more funding, or more time. But in many cases, the real issue is that their product claims are broader than the evidence they already have. In this episode, Hakeem unpacks Jordan Morrison's decision-making framework and explains why narrowing your claims could help you achieve regulatory approval, generate revenue sooner, and build momentum for future growth. Listeners will discover: Why regulatory hurdles aren't always the biggest obstacle to getting your MedTech product to market How to match your product claims to the evidence you already have Why securing one well-supported claim can accelerate commercialisation and create a platform for future expansion Play this episode now to discover how a more focused regulatory strategy could help you get your MedTech product to market faster and build commercial momentum. This keeps the focus where your audience is: commercialising MedTech products , rather than getting lost in the technicalities of regulation.
Transcribed and scored by The B2B Podcast Index.
One thing you're gonna learn in today's episode is why narrowing your product claims could get your MedTech product to market faster. Welcome to Clinician to CEO, the podcast helping clinicians simplify your go-to-market strategy so that you can stop guessing and turn your working prototypes into international MedTech businesses. I'm your host, Hakeem Aade. Let's get started.
So three things you're gonna discover today is, number one, why regulatory hurdles aren't always the real problem that you think they are. Number two, how to make progress without starting from scratch. Number three, why getting one claim to market is often better than chasing 10. So at the end of every one of my guest episodes, I ask them to tackle a real world commercial decision.
There isn't always a right answer, and the goal is to understand how they think. So today's scenario comes from my conversation with Jordan Morrison, and here's the challenge that I gave her you are advising a startup with a promising medical device. Early trials are encouraging, but regulatory hurdles are slowing progress. So do you, A, push ahead with a full submission; do you, B, generate more clinical evidence; do you, C, adapt the products based on clinical feedback; or do you, D, partner with a larger company to push it through?
What's your choice and why? so here's Jordan's answer Well, I don't know if I'm gonna follow any of those choices, but that's what makes Samira special. So one of the things I do is I have agnostic experts from the very beginning. So when you, choose to work with me, my people, my regulatory, 'cause you said this is a regulatory issue, my regulatory people are gonna review what you've already done, and then they're going to give it a memo that is investor-facing deliverable to say, "Hey, this is the pathway."
So now I can look against what your team has said and what my team has said, and I can now start to reconcile that. So if you're saying regulatory hurdles, I wanna know what are those hurdles. Is this a breakthrough designation, and we're trying to pave a way that hasn't been done before? Can we make it something that's a predicate?
I think a lotta times, too, especially in regulatory, there's easy fixes. Sometimes we're so busy trying to, like, solve world hunger, that maybe we just solve hunger in, you know- One state or one country. Like, let's solve Italy's problem, and then we can solve all of the world, right? So I think a lot of times, when it's regulatory hurdles, the hurdles I see are they've spent a lot of money on a regulatory consultant that's telling them that they now don't have the data they need for the submission.
That's what I see a lot is like, okay, I need X validation data to, to back up your claims. What if we take the data you have and find claims that support the data you have? So maybe you're not, again, maybe you're not hitting the whole entire market on the first iteration, but you have one product doing one claim really, really well. Your, your data's there.
You obviously didn't build something that hurt people, right? You would've stopped everything yesterday. So if it's a regulatory hurdle, chances are your claims are too broad, and that can be addressed by a second and third iteration. So the best thing to do is save your money.
What can you do with the data you have? What can you get for the least amount of money? 'Cause this is a bargaining, negotiating thing, and how do we continue to move forward? Like, do not lose that, forward progression.
So maybe it loo- again, pivot. Maybe it looks different. Maybe you're not gonna get a clearance that says you can solve all of the cancers in all of the world at all of the same times with one little pill. But maybe your, your clinical data showed, well, there is a decrease in reoccurrence of breast cancer.
So now you've, you've changed that claim down. You've narrowed it down. You're actually getting the data that supports it. You've not wasted the money in the bill that you've done so far, and you can keep moving forward.
And now commercialize with just that one little claim and that one little piece. Get some revenue coming in so now you can build the second and third iterations and keep doing the research and development. That's a win across the board. So it's not a hurdle.
It's, it's a literally, it's a pivot. So what I would do is I start with my independent agnostic overview as part of my due diligence, and I say, "Do they agree with what your person is saying?" And then how do we salvage it? Like, how do we fix it?
That's all, that's the real answer. Instead of blindly, again, going straight into, Well, we already started this. This is what our clinical trials are. This is what we have to do.
This is our only pathway forward." There's, there's a, what is it? 15 ways to skin a cat? That always makes me nervous about skinning cats.
Yeah. But there's, there's multiple ways to get to the end, to be clear, right? I try to create a roadmap, but the reality is it's just forward momentum. Don't worry about where the end point is.
Don't worry about what the finish line looks like. You will never be finished. Look at where do I put the next brick to move forward? Where do I, where do I build that next roadmap?
Just get that forward progress. Take what you have, polish it, fix it, salvage it. So now my thoughts. What I really liked about Jordan's answer was the fact that she didn't pick one of the four options that I gave, but she actually challenged the question because before deciding what to do next, what she wanted to understand was why the regulatory process had actually stalled.
Was it a lack of evidence, or were the product claims simply too ambitious for the evidence they already had? And that distinction really matters because a lot of med tech companies assume that the answer is another clinical trial, more funding, or more time. And sometimes it is, but sometimes the quickest route to market Is matching your claim to the evidence that you've already generated. And Jordan's point was really simple.
What you need to ask yourself is: what does our evidence prove today? Now, if your data strongly supports one indication, focus on that. Get that claim through, start generating revenue, build real world evidence, then expand from there. That is often a far better strategy than trying to prove everything in version one.
So this week's action for you, if you choose to accept it, is if you're facing any regulatory or commercial hurdles, stop for fifteen minutes and ask yourself, number one, are our product claims bigger than the evidence that we have today? Number two, what's the strongest claim our current evidence genuinely supports? And number three, what would getting that one claim to market unlock for the business? because sometimes the fastest way forward isn't collecting more data, it's just making better use of the data that you already have.
So my closing thought is that getting to market isn't about proving everything. It's about proving enough, i.e., enough to help patients, enough to generate revenue, enough to build the next version.
So before asking, What more do we need?" Ask, What can we prove with what we already have?" Because in med tech, momentum is often your biggest competitive advantage And if you're building a MedTech business and you're not sure whether your next move should be around evidence, market access, commercialization, distributor strategy. Or adoption.
Do not guess. Book a healthcare export accelerator diagnostic Call with me. Use my link in the show notes. And in that session I'll help you identify the specific constraints blocking your momentum and the commercial move most likely to unlock your progress.
Thanks for tuning in. Until next time, thanks for listening. Keep challenging your assumptions and keep growing.
Other episodes covering the same guests and topics, from across The B2B Podcast Index.
#209 | 5 Lessons You Should Know Before Commercializing & Exporting Your MedTech Product (For Clinicians)37 / 100#207 | The Ugly Baby Problem Every MedTech Founder Must Avoid When Exporting (For Clinicians)86 / 100#206 | 5 Lessons Every MedTech Company Should Learn Before Exporting to Japan52 / 100#205 | The #1 Mistake MedTech Companies Make When Choosing Export Markets66 / 100#204 | Why Japan Is Easier to Export MedTech Products To Than Most Companies Think85 / 100
